Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study To the Editor: Topical vasodilators may act as an adjuvant therapy for Raynaud phenomenon (RP). Several trials have shown the benefits of topical nitrates, 1,2 but there is a lack of evidence for the efficacy of other topical agents. The objective of the study was to compare the vasodilator efficacy of topical 10% nifedipine versus 5% sildenafil in subjects with secondary RP associated with connective tissue disease. A prospective study was performed including 10 patients with secondary RP. We excluded tobacco smokers, patients with primary RP, hypotension, hypertension, myocardial infarction, stroke, or arrhythmia. Patients who were being treated with a vasodilator were required to discontinue use for at least 24 hours before randomization. Patients' hands were randomized to treatment with 5 g of 10% nifedipine cream on one hand and 5 g of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve topical absorption, leaving the thumbs out of the gloves without any cream (control group). All patients underwent a high-frequency color Doppler ultrasound examination before and 1 hour after topical application. The temperature of the waiting and examination rooms was set at 668F. The radiologist was blinded to the treatment groups, and subsequent analysis was blinded to ultrasound results. The primary outcome was the improvement of blood flow in digital arteries using the peak systolic velocity. The secondary outcome was the increase of vessel diameter. For each hand, we obtained the differences of digital artery blood flows and diameters at baseline and after 60 minutes. Therefore, mean differences \0 indicated that the study cream was effective. Our findings are summarized in Tables I and II. Topical sildenafil significantly increased blood flow by 9.2 mm/sec (P \ .0083), while a trend toward improvement was observed for diameter (P ¼ .0695). After topical nifedipine, there was no significant improvement in blood flow or diameter. Five of 10 hands using nifedipine experienced sensation of heat and 6 of 10 hands with sildenafil developed a tingling sensation. No serious adverse effects were detected. Secondary RP is often refractory to standard therapies and is a therapeutic challenge. Current evidence supports the use of an oral calcium-channel blocker (eg, nifedipine) or synthetic prostacyclin analogue (iloprost), but substantial evidence is lacking for other agents. 3 There is limited evidence regarding the effectiveness of topical vasodilators for the management of RP. Only 1 study investigated the vasodilator effect of nifedipine gel on patients with RP, demonstrating an improvement of capillary circulation. 4 No previous study has evaluated the efficacy of topical sildenafil. We found that 5% sildenafil cream improved the digital arterial blood flow in patients with secondary RP, suggesting local vasodilatation. A limitation was the small sample size. Although there was a brief washout period, the cohort ideally would have A novel treatment for limited mouth opening due to facial fibrosis: A case series
To the Editor: Limited mouth opening (LMO) is a frequent consequence of progressive facial fibrosis due to systemic sclerosis (SSc) and other connective tissue diseases. LMO affects the daily lives of patients by altering their physical appearance and impairing their ability to eat and phonate. LMO can also have a significant impact on the health of patients by making it difficult for them to perform regular dental hygiene and undergo dental examinations. Current treatment options are few and of low efficacy and reliability. 1 Our first patient presented 3 years ago with LMO as a result of SSc, and her initial oral aperture was 3.0 cm. She had previously received perioral botulinum toxin A (BTX-A) for cosmetic treatment of rhytids and serendipitously noticed decreased constriction of her oral aperture. Given this observation, the patient was initially treated conservatively with 1.25 units of BTX-A in 4 perioral sites, and an improvement in constriction was again noted. Over the next 2 years, the procedure was refined to 2.5 units of BTX-A in 8 evenly spaced sites as shown in Fig 1; the patient's oral aperture has increased to 4.5 cm. Over the last year, we have treated an additional 4 patients; their characteristics are summarized in Table I .
The mechanisms by which BTX-A improves LMO are uncertain but are thought to involve its effects on muscles and fibroblasts. BTX-A has well known paralytic effects that when applied to the orbicularis oris, likely reduces that muscle's ability to oppose mouth opening. Additionally, 2 in vitro 
